Virological Suppression and Its Associated Factors of Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational Retrospective Study in Ethiopia
Open Access
- 1 June 2021
- journal article
- research article
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 13, 709-717
Abstract
Background: Toxicity, treatment failure, and resistance to existing HIV treatment regimens have become a challenge in resource-limited settings. As a result, a dolutegravir based regimen has recently been utilized. However, there is a paucity of evidence in sub-Saharan countries regarding its virological suppression. Thus, this study aimed to assess virological suppression and associated factors of dolutegravir based regimen. Methods: A retrospective follow-up study was conducted on 349 individuals. They were selected using a systematic random sampling technique among all treatment-experienced adult HIV patients who were on a dolutegravir based regimen. From this, 81.4% of them were virologically suppressed before the initiation of dolutegravir based regimen. The study was carried out at twelve months of therapy after shifting to dolutegravir based regimen (TDF-3TC-DTG) during the period May 2018–August 2020 at Debre Markos referral hospital. Retrospective data before and after dolutegravir based regimen initiation were collected from their medical records. The time on dolutegravir based regimen was one year. Bivariable and multivariable logistic regression was used to identify factors. Variables with p < 0.05 were considered statistically significant. Results: From a total of 359, 349 participated (97.2%) in the study, and the mean age of the participants was 40.28 ± 11.6 years. Totally, 192 (55.0%) of them were female. The proportion of virological suppression was 92%. Good adherence (participants who reported an intake of ≥ 95% of the prescribed medication) (AOR=6.2, 95% CI: 1.93, 20.11) and overall duration of ART (AOR=1.02, 95% CI: 1.01, 1.04) were associated with virological suppression. Conclusion: Dolutegravir based regimen maintains high virological suppression. Adherence and duration of ART were associated with virological suppression. Therefore, designing effective mechanisms to maintain virological suppression is important.Keywords
This publication has 28 references indexed in Scilit:
- Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settingsBMC Public Health, 2014
- Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and AdultsDrugs, 2014
- Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitorsAIDS, 2014
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionNew England Journal of Medicine, 2013
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyThe Lancet, 2013
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Severe obesity, gestational weight gain, and adverse birth outcomesThe American Journal of Clinical Nutrition, 2010
- A Caution Regarding Rules of Thumb for Variance Inflation FactorsQuality & Quantity, 2007
- Long-Term Effects of Highly Active Antiretroviral Therapy in Pretreated, Vertically HIV Type 1-Infected Children: 6 Years of Follow-UpClinical Infectious Diseases, 2006
- The Fitness, Obesity, and Health EquationJAMA, 2004